Self-Regulating Mammalian Cell Line for Biologics
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current mammalian cell lines used for recombinant protein production are inefficient and costly, particularly for next-generation biologics, due to constitutive gene expression systems that fail to coordinate transcription with cellular metabolism, leading to cellular stress and poor product quality.
Innovation Solution
A genetic control circuit using a repressor polypeptide, such as dCas9, that reduces the transcription rate of recombinant protein genes in response to cellular stress, alleviating biosynthetic load and allowing optimal co-ordination with cellular capacity, thereby improving yield and product quality.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If constitutive gene expression systems are used to continuously transcribe recombinant protein genes, then high productivity is achieved, but cellular stress increases and product quality deteriorates
Solution Approach 1:
The patent implements dynamic gene expression control by replacing constitutive promoters with inducible promoters that respond to cellular conditions. The system dynamically adjusts transcription rates based on cellular stress signals, metabolic state, and protein folding capacity, allowing the cell to optimize between productivity and quality control in real-time.
Solution Approach 2:
The patent employs feedback mechanisms where cellular stress responses (such as UPR activation) directly regulate gene expression levels. When cellular stress or misfolded protein accumulation is detected, the system automatically reduces transcription rates through stress-responsive promoter elements, preventing overwhelming the cell's folding capacity and maintaining product quality.
2Productivity
If high levels of recombinant protein are continuously synthesized, then productivity increases, but the unfolded protein response is activated and overall yield decreases
Solution Approach 1:
The patent implements periodic gene expression cycles where transcription is activated during phases of adequate cellular capacity and automatically downregulated when stress thresholds are reached. This periodic on-off pattern, controlled by stress-responsive regulatory elements, allows the cell to recover and maintain folding capacity while still achieving high cumulative production over time.
Solution Approach 2:
The patent changes the operational parameters of gene expression by using promoters with different stress-response thresholds and kinetics. This allows optimization of expression levels to match cellular capacity under different culture conditions, maintaining product quality while maximizing yield through parameter tuning rather than constant high-level expression.
3Ease of manufacture
If gene expression is not coordinated with cellular metabolism, then simple constitutive systems are easier to implement, but product quality attributes such as glycosylation and folding are poor
Solution Approach 1:
The patent enables the cell to self-regulate gene expression by utilizing its own endogenous stress response pathways and metabolic sensors to control transcription. The system automatically coordinates expression with cellular capacity without requiring external intervention, allowing the cell to serve itself in optimizing both productivity and product quality through its native regulatory machinery.
Data Source
AI summary
Disclosed are genetic control circuits, cells, and methods that use a repressor polypeptide to reduce the transcription rate of an exogenous therapeutic polypeptide encoding gene in response to a change in condition.